quotes and stock data delayed 15 minutes
Burn Rate (Qtr)
We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody. Lenzilumab is a monoclonal antibody that has been proven in animal models to neutralize GM-CSF.
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
See what the community is saying - click to see full post